Virtual Presentation
Zoom Meeting
Register for Instructions and Zoom Meeting Link

Date: Wednesday, September 29, 1:00 pm

Program Presenter: Chris Chapman, M.D. President, Director and Chief Medical Officer and Adam Kaplin, M.D., Ph.D. Chief Scientific Officer

mymd.com

PRESENTING

Chris Chapman, M.D. President, Director and Chief Medical Officer
Chris Chapman, M.D. was appointed as President and Chief Medical Officer of MyMD Pharmaceuticals effective November 1, 2020. Prior to joining MyMD and since 1999, Dr. Chapman has also served as the Chief Executive Officer of Chapman Pharmaceutical Consulting, Inc., a consulting organization that provides support to pharmaceutical and biotech companies in North America, Europe, Japan, India and Africa on issues such as product safety, pharmacovigilance, medical devices, clinical trials and regulatory issues. In addition, from 2003-2004, Dr. Chapman served as the Associate Director of Drug Safety, Pharmacovigilance, and Clinical Operations for Organon Pharmaceuticals, where he was responsible for the supervision of four fellow M.D.s and 10 drug safety specialists.

Adam Kaplin, M.D., Ph.D., Chief Scientific Officer
Adam Kaplin, M.D., Ph.D. was appointed Chief Scientific Officer of MyMD effective December 18, 2020. Prior to joining MyMD, Dr. Kaplin has served in a number of positions at John Hopkins University, including Principal Neuro-Psychiatric Consultant to the Johns Hopkins Multiple Sclerosis Center of Excellence, Director of the Johns Hopkins Ketamine Clinic and the Departments of Psychiatry & Neurology at Johns Hopkins University School of Medicine, positions he has held at various times from 2002 to present. In addition, since 2019, Dr. Kaplin has served as Adjunct Faculty at the George Mason University Department of Global and Community Health. Dr. Kaplin has also served as Co-Founder of numerous healthcare related startups, including, from 2018 to present, REWARD Pathways Inc., a company devoted to addiction treatment development focused on a combined eHealth and medicine approach to curing addiction, and from 2016 to present, Hollinger Kaplin Benjamin & Bond, an eHealth software development company. Dr. Kaplin’s research focuses on the investigation of the biological basis of immune mediated depression and cognitive impairment by using MS as the model. Dr. Kaplin has also been active for over a decade in the development and application of health information technology to mental health, combining this work with providing neuropsychiatric consultation and ongoing care of patients with MS spectrum disorders. Dr. Kaplin’s original research has been published over 40 times in several different publications, and he has authored or co-authored numerous review articles and textbooks. Dr. Kaplin received his B.S. in Biology from Yale University, graduating cum laude in 1988, and received his M.D. and Ph.D. from the Johns Hopkins University School of Medicine in 1996.

COMPANY OVERVIEW

MyMD Pharmaceuticals is a clinical stage pharmaceutical company committed to extending healthy lifespan. Currently, we are developing through the FDA approval process and expect to commercialize two therapeutic platforms based on well-defined therapeutic targets, MYMD-1 and Supera-CBD.

MyMD, Inc. (NASDAQ: MYMD) seeks to enhance shareholder value not only through exceptional business performance and practices, but also through responsible and effective communication with its shareholders. The latest company information relevant to the individual and institutional investor includes stock price and history, upcoming events and presentations and financial documents.